Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients

Transplantation

Volumn 86, Issue 1, 2008, Pages 130-136

  Braudeau, Cécile ^a   Ashton Chess, Joanna ^a   Giral, Magali ^a   Dugast, Emilie ^a   Louis, Stephanie ^a   Pallier, Annaick ^a   Braud, Christophe ^a   Moreau, Anne ^b   Renaudin, Karine ^b   Soulillou, Jean Paul ^a   Brouard, Sophie ^a  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic rejection; Kidney; Tolerance; Toll like receptor

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOID DIFFERENTIATION FACTOR 88; RAPAMYCIN; STEROID; TACROLIMUS; TOLL LIKE RECEPTOR 4; MYD88 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOPSY; BLOOD; BLOOD SAMPLING; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HISTOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION TOLERANCE;

EID: 49849103955     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817b8dc5     Document Type: Article

References (24)

1. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
2. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774.
3. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
4. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
5. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor neph-rotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
6. GiralM,Nguyen JM, KaramG,etal. Impactof graft massonthe clinical outcome of kidney transplants. J Am Soc Nephrol 2005; 16: 261.
7. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460.
8. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987.
9. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral Blood mononuclear cells and sensitivity to CpG oligodeoxynucleoti-des. J Immunol 2002; 168: 4531.
10. Tesar BM, Jiang D, Liang J, et al. The role of hyaluronan degradation products asinnate alloimmune agonists. AmJTransplant 2006;6:2622.
11. Walker WE, Nasr IW, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006; 177: 5307.
12. Goldstein DR, Tesar BM, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571.
13. GoldbergA,Parolini M, Chin BY, et al. Toll-like receptor4 suppression leads to islet allograft survival. Faseb J 2007; 21: 2840.
14. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847.
15. Tesar BM, Zhang J, Li Q, et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Tolllike receptor signal adaptor protein. Am J Transplant 2004; 4: 1429.
16. Samstein B, Johnson GB, Platt JL. Toll-like receptor-4 and allograft responses. Transplantation 2004; 77: 475.
17. Methe H, Zimmer E, Grimm C, et al. Evidence for a role of Toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004; 78: 1324.
18. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67: 2454.
19. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168: 628.
20. Chen L, Wang T, Zhou P, et al. TLR engagement prevents Transplantation tolerance. Am J Transplant 2006; 6: 2282.
21. Marshak-Rothstein A.Tolling for autoimmunity-prime time for 7.Immunity 2006; 25: 397.
22. Zipris D, Lien E, Xie JX, et al. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005; 174: 131.
23. Kobayashi M, Kweon MN, Kuwata H, et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003; 111: 1297.
24. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 1131.